DoH Policies screened during the period: 1st January 2017 to 31st March 2017

In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).

Documents

The Adoption and Children Bill
PDF (516 KB)

Individual Funding Request (IFR) process
PDF (90 KB)

NICE Clinical Guideline CG19 - Dental checks: intervals between oral health reviews
PDF (163 KB)

NICE Clinical Guideline CG65 - Hypothermia: prevention and management in adults having surgery – Addendum
PDF (173 KB)

NICE Public Health Guideline NG55 - Harmful sexual behaviour among children and young people
PDF (166 KB)

NICE Clinical Guideline NG57 - Physical health of people in prison
PDF (170 KB)

NICE Clinical Guideline NG59 - Low back pain and sciatica in over 16s: assessment and management (updates & replaces CG88)
PDF (163 KB)

NICE Clinical Guideline NG61 - End of life care for infants, children and young people with life-limiting conditions: planning and management
PDF (163 KB)

NICE Clinical Guideline NG62 - Cerebral palsy in under 25s: assessment and management
PDF (165 KB)

NICE Technology Appraisal TA421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (review of TA295)
PDF (173 KB)

NICE Technology Appraisal TA422 - Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (review of TA296)
PDF (164 KB)

NICE Technology Appraisal TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (review of TA250)
PDF (165 KB)

NICE Technology Appraisal TA424 - Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
PDF (189 KB)

NICE Technology Appraisal TA425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (review of TA241 & part review TA70)
PDF (168 KB)

NICE Technology Appraisal TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (review of TA251 & part review of TA70)
PDF (167 KB)

NICE Technology Appraisal TA427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (review of TA338)
PDF (186 KB)

NICE Technology Appraisal TA428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
PDF (191 KB)

NICE Technology Appraisal TA429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
PDF (165 KB)

NICE Technology Appraisal TA430 - Sofosbuvir-velpatasvir for treating chronic hepatitis C
PDF (197 KB)

NICE Technology Appraisal TA431 - Mepolizumab for treating severe refractory eosinophilic asthma
PDF (197 KB)

NICE Technology Appraisal TA432 - Everolimus for advanced renal cell carcinoma after previous treatment (review of TA219)
PDF (164 KB)

NICE Technology Appraisal TA433 - Apremilast for treating active psoriatic arthritis (rapid review of TA372)
PDF (166 KB)

Delivery plan arising from Programme for Government 2016-21 indicators 2,3,4 and 7
PDF (691 KB)

PFG Indicator 5 - Improve the quality of the healthcare experience – Development of Quality Health and Social Care Experience Framework
PDF (419 KB)

PFG Indicator 6 – Improve mental health
PDF (395 KB)

PFG Indicator 10 - Improve support for Looked After Children
PDF (323 KB)

Help viewing documents